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With the rapid emergence of antibiotic resistant bacteria affecting people around the 
world, research into new therapies using bacteriophages (phages) is increasing in the United 
States. Phages are viruses that can only infect bacteria and are able to co-evolve alongside the 
bacteria they infect. A researchers’ ability to pinpoint which phage to use in the therapy is 
important to combat an infection effectively. To do so, the genes that control the interaction 
between phages and the bacteria they infect, such as receptor binding proteins on the surface 
of a bacterial cell, need to be identified. Transposon mutagenesis was used in our study to find 
the receptor binding protein of Bacillus thuringiensis kurstaki (Btk). Btk was chosen as the 
bacterial host because it is a naturally occurring soil bacteria that is commonly used as an 
insecticide in agriculture, but is nonpathogenic to humans. The bacterium is also a close relative 
to Bacillus anthracis, the causative agent of anthrax, and may share some phages. Using the EZ-
Tn5TM <R6Kyori/KAN-2> Tnp transposon kit, 134 individual mutant colonies were isolated on 
kanamycin plates. Virulent bacteriophage Riley, a well-characterized phage infecting BtK, was 
used to find phage-resistant bacteria in the mutant population. Three mutants, 1041, 1043, and 
1221, were found to be resistant to bacteriophage Riley and will be further studied to 
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On September 3, 1928, the major discovery of penicillin was made by Alexander Fleming 
that would soon be deemed the miracle drug (Aminov, 2010). For decades after that discovery, 
the western world has depended solely on antibiotics to treat bacterial infections. What many 
did not realize was that every time a person was prescribed antibiotics, it increased the risk of 
bacteria becoming resistant and, consequently, deadlier to the human population. Due to the 
Cold War, many of the advances in antibiotics did not reach past the iron curtain into Eastern 
Europe. Consequently, research into bacteriophage (phage) therapy increased, instead of being 
pushed to the side like it was in the West  (Nobrega, Costa, Kluskens, & Azeredo, 2015). With 
the increase of the number of antibiotic resistant bacterial strains, phages are once again being 
looked at as a treatment for bacterial diseases. 
Unlike antibiotics, that have the tendency to kill more than just bacteria causing the 
infection, bacteriophages have a high specificity to the bacteria they infect (Nobrega et al., 
2015). Their high specificity is also a limitation in phage therapy because they can only infect 
one type of bacteria while an infection may include multiple types of pathogenic bacteria. To 
combat this problem many scientists are creating phage cocktails that have multiple different 
types of phages that can infect and destroy different types of bacteria (Chan, Abedon, & Loc-
Carrillo, 2013). Another advantage to bacteriophages is that they only replicate at the site of 
infection. Phages are self-limiting and self-dosing, preventing them from persisting when their 
specific bacterial pathogen becomes absent (Nobrega et al., 2015). From a developmental point 
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of view, phages have the advantage of rapid isolation, versatility of formulation and application, 
and lower developmental costs than antibiotics (Nobrega et al., 2015). 
Phage therapy has the advantage of being able affect multi-drug resistant bacteria and 
biofilms because phages have specific receptor binding sites that allow them to infect a 
bacterium even if it is resistant to antibiotics. Phages have a general lower tendency to induce 
resistance and cross-resistance to antibiotics (Nobrega et al., 2015).  Phage-resistance can, 
however, occur in bacterial cells if the bacterium uses the Clustered Regularly Interspaced Short 
Palindromic Repeats (CRISPR) system that is able to cause the degradation of the inserted 
phage DNA or RNA, or phage absorption is blocked due to the mutation or loss of the bacterial 
receptor on the surface of the bacterial cell (Nobrega et al., 2015). To combat bacteria’s natural 
way of immunizing themselves against phages, a proposed solution is to genetically engineer 
the phages using the CRISPR system.  
Before genetic engineering can be done, research on the genes that control phage and 
interaction with the bacterial cell must be completed. An important protein for the attachment 
of the bacteriophage to the bacteria’s cell wall is the Receptor Binding Protein (RBP) located on 
the surface of the bacterial wall. The first step in the infection by a bacteriophage is the 
adsorption of the phage to the host cell (Bielmann et al., 2015). RBP is recognized by phage 
receptor and allows the phage to attach to the cell wall (Bielmann et al., 2015). The RBP 
recognition and binding is extremely specific, and high affinity is required for rapid and efficient 
virus attachment (Bielmann et al., 2015).  According to Bielmann, the precise mechanism by 
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which a phage particle recognizes, adsorbs to, and infects a bacterial cell is only poorly 
understood, especially for phages infecting Gram-positive pathogens (Bielmann et al., 2015).  
Though they are difficult to identify using 
standard procedures, RBPs can be used as 
diagnostic tools and therapeutics in the 
biotech industry (Sacher, 2016). For these 
therapeutics to be successful, the structures 
of the host cell that will allow phage 
interaction must be analyzed. (Sacher, 2016).  
Transposon Mutagenesis  
To analyze RBPs, the technique of transposon mutagenesis can be used to find and 
isolate the gene. Transposons are genetic elements that go through the recombination process 
of transposition in which they can relocate from one genomic location to another (Reznikoff, 
1993)(Hayes, 2003). Transposons are found in both prokaryotic and eukaryotic cells and can be 
used as in vivo or in vitro interrupters (Hayes, 2003). Tn5 is a type of transposon that moves 
from its resident position to  another location by a cut-and-paste mechanism (Hayes, 2003). The 
Tn5 transposon from the EZ-Tn5 <R6kγori/KAN-2> transposon kit contains the kanamycin 
resistant gene KANR that allows antibiotics resistance to be used as a selection phenotype (Tnp 
& Kit, 2017). The R6kγori gene allows the transposon to self-ligate into a plasmid after the DNA 
from the mutant is  extracted and sheared so that it can be transformed into E. coli to be 
Figure 1: Rescue Cloning of Interrupted Gene and 
Transposon (TNP & KIT, 2017) 
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rescued, as seen in Figure 1 (Tnp & Kit, 2017). The 
transposon map (Figure 2) indicates that the KANR 
gene and the R6kγori gene fall in the middle of the 
transposon’s genomic sequence. The additional 
genes allow the researcher to ensure that the 
transposon has interrupted a gene. The Tn5 
transposon can be inserted into the bacteria’s 
chromosome using electroporation (Figure 3). 
Electroporation is the process of using electrical 
pulses to create pores that allow genetic material to permeate the bacterial membrane of 
electrocompetent cells (“Electrocompetent 
Cells,” n.d.). The EZ-Tn5 transposase is then 
activated by the Mg2+ that is located in the cell’s 
environment and randomly inserts into the 
host’s DNA (Tnp & Kit, 2017). The cells that took 
up the transposon can be grown on kanamycin 
(KAN) plates so that the genes that were 
interrupted can be found and analyzed.  
  
Figure 2: Ez-Tn5 <R6kγori/Kan-2> 
Transposon (Tnp & Kit, 2017) 
Figure 3: Transposon mutagenesis using 




Bacillus thurgiensis kurstaki and Bacteriophage Riley  
Bacillus thurgiensis kurstaki (BtK) (Figure 4) is a Gram-
positive bacterium that is found abundantly in soil. It is used 
in industry as a natural insecticide to certain types of 
caterpillars (Olkowski, Daar, & Olkowski, 2009).  It is a non-
pathogenic bacterium that can be safely handled in a 
Biosafety Level 1 lab. Since it is in the lowest Biosafety Risk 
Group, BtK is a safe candidate to create mutants with transposon mutagenesis.  
Riley (Figure 5)  is a myoviris bacteriophage that was 
discovered and characterized by students at Mary Washington 
University. It is a virulent phage that only goes through the lytic 
cycle. This attribute allows Riley to be a candidate for phage 
therapy because it would infect and destroy the bacteria 
without going into the lysogenic cycle, which could leave some 





Figure 4: Bacillus thurgiensis 
Kurstaki (Sahay, 2013)  
Figure 5: Bacteriophage Riley 




The main purpose of this project was to further our knowledge about the genes that 
allow the interactions between bacteriophages and the bacteria they infect. The overall goal 
was to find the receptor binding protein using transposon mutagenesis to construct mutants 






Multiplicity of Infection: 
 The Multiplicity of infection (MOI) for Bacillus thurgiensis kurstaki (BtK) was calculated 
to find the amount of BtK needed to infect LB plates. To find the MOI, 3.0 mL of enriched BtK 
and SM buffer (100mM NaCl, 8 mM MgSO4·7H2O, 50 mM Tris-Cl (1 M, pH 7.5), 0.01% (w/v) 
Gelatin (2%, w/v), 1 liter H2O) was placed in a tube labeled 100. A 10-fold dilution out to 10-4 
was then made with SM buffer and the bacterial culture.  A Bausch and Lomb Spectronic 20 
spectrometer was used to measure the optical density (OD) at 600nm for each dilution.  Then 
100 µL of each dilution was spread on separate LB plates. The plates were then placed into an 
incubator at 37°C for 24 hours. The titer was then calculated for the 10-4 dilution using the 
following formula: (
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠




) × 𝑡ℎ𝑒 𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟  
Testing Bacteriophages: 
  The bacteria culture was diluted to 10-2 and 100 µL of the dilutions 100 to 10-2 were 
pipetted into 5 mL top agar and poured onto separate plates. Five microliters of high titer lysate 
of bacteriophages Riley, Troll, Megaron, and CAM003 were placed onto designated spaces on 
each plate. The plates were then placed into the incubator at 37°C for 24 hours. The test was 
used to see which phage would infect the bacteria with the clearest spot with the given 





Transposon Mutagenesis:  
 The purpose of this protocol was to prepare the cells for electroporation and then deliver 
the transposon. The BtK cells were prepared for electroporation by inoculating a colony of BtK in 
10 mL of LB in a 125-mL flask and then incubating the culture overnight at 37°C in a shaking 
incubator at 250 RPM. Five hundred milliliters of BHI were incubated overnight as well. After 24 
hours, 2 mL of the BtK culture were pipetted into the heated BHI flask and incubated at 28°C in 
the shaking incubator at 300 RPM. The cultures were monitored until the OD600 reached 0.3 OD, 
which is approximately 1.0 x 107cells/mL as calculated by colony forming units. At this point, the 
culture was chilled on ice for 10 minutes. The cells were then transferred into two chilled 250 mL 
centrifuge bottles and centrifuged at 4°C for 10 minutes at 10,000 x g to form a pellet at the 
bottom of the tube. After discarding the supernatant, the pellet was resuspended with 50 mL of 
sterile ice-cold EP buffer (0.5 mM K2HPO4–KH2PO4, 0.5 mM MgCl2, 272 mM Sucrose). The cells 
were pelleted as before with the chilled centrifuge. After pelleting the cells, the supernatant was 
discarded and the pellet was resuspended in 15 mL of sterile, ice cold EP buffer. The cells were 
then transferred into 40 mL Oak Ridge tubes and centrifuged for 10 minutes at 10,000 x g. The 
supernatant was discarded and the pellet was resuspended in 0.5 mL of ice cold EP buffer and 
kept on ice.  
 To electroporate the cells, 1 µL of transposon DNA was pipetted into 100 µL of the 
electrocompetent BtK cells. The solution was mixed and incubated on ice for 5 to 10 minutes. 
After incubating the cells, 100 µL of the transposon-cell suspension was transferred to a chilled 
0.2 cm cuvette on ice. A microcentrifuge tube for each sample was prepared with 2.0 mL of LB 
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broth and incubated at room temperature. The cuvette was tapped to get the solution to the 
bottom of the cuvette. The Bio-RAD Gene Pulser X cell (Bio-Rad, [Hercules, CA]) was used with a 
Bacillus-specific protocol from the instrument manufacturer to electroporate the cells. The 
cuvette was then placed in the ShockPod and the chamber lid was closed. The pulse parameter 
was checked to see if the time constant was approximately 8.6 milliseconds and the voltage 
was approximately 1.0 KV. After pressing the pulse button, the cuvette was removed from the 
chamber and 200 µL of the room temperature LB broth was immediately added to the cuvette. 
The cells from the cuvette were then transferred to the tube containing the LB broth. The 
process was then repeated for the negative control (no DNA added to the bacterial cells). The 
two tubes were then incubated for 1.5 hours at 37°C in the shaking incubator at 250 rpm. The 
cell cultures were then plated on kanamycin-LB (50 ug/mL) plates at 100 µL per plateand 
incubated at 37°C for 48 hours.   The colonies that grew were cultured eight at a time on KAN 
plates.  
Bacteriophage Resistance testing:  
 The mutants were named by taking the number of their plate and their position on the 
plate. An example of this would be mutant 1043 where the mutant was on plate 10 as the 43rd 
mutant cultured. The next step was to use full plates infections (FPI) to find mutants that are 
resistant to bacteriophage Riley. The FPI started by labeling five microcentrifuge tubes 100 to 
10-4. For the 100 microtube, 100 µL of LB was pipetted into the tube. Ninety microliters of LB 
was pipetted into the rest of the labeled tubes.  Eight mutants were then picked and put into 
one 100 tubes to make a pool. Ten microliters from the 100 tube was pipetted into the 10-1 
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tube. This was then repeated for the rest of the dilution series. One hundred microliters of 
phage HTL was pipetted into each tube. After the tubes were mixed by vortexing, 190 µL of 
each dilution was pipetted onto separate KAN plates and incubated at 37°C for 24 hours. This 
technique was then repeated for the rest of the mutants, but only using dilutions 10-3 and 10-4 
since their lawns had the most coverage on the plate.  
 The colonies were then tested against phage Riley using spot tests to identify mutants 
that were resistant to the bacteriophage. To do this, the mutant colonies were individually 
picked and then placed in 5 µL of LB broth and incubated in the shaker at 37°C for 48 hours. The 
cultures were then plated on KAN plates by pipetting 50 µL of the culture onto the plate and 
spread by using an L-shaped spreader. Five microliters of the high titer lysate (HTL) of Riley was 
then spotted on the plate and left to dry. The plates were placed in the incubator at 37°C for 48 
hours.  The spot test protocol was repeated twice more using 100 μL of the culture on the 
plates until there were 8 mutants that showed consistent and stable phage resistance.  After 












In this study, a suitable phage was chosen and optimized for infectivity against BtK.  Lack 
of infection by this phage was used to screen a transposon mutant library of BtK.  The process 
yielded three resistant mutants, which are currently being analyzed. 
Multiplicity of Infection and testing bacteriophages:  
 BtK was diluted to 10-4 and was determined that the 
10-4 dilution yielded a confluent lawn of approximately 
7.6 x 106 cfu/mL. Bacteriophage Riley was chosen as 
the phage to test against the mutants (Figure 6). The 
MOI chosen was 100 since it had the most consistent 
lawn coverage, as seen in Figure 6.  
Transposon Mutagenesis:   
The time constant for the control BtK for 
electroporation was 9.6 msec and the voltage was 989 
V. The time constant for the bacteria-plasmid solution 
was 8.1 msec and the voltage was 986 V. A total of 
134 mutants (Figure 7) were produced in two 
experiments. A few cells were found on the control, 
but were not consistent enough throughout the plates 





Figure 6: Dilution 100 with phage spots 
Figure 7:  7 out of 134 Btk mutant 




 Mutants from plates 10, 11, 12, and 13 were able to grow on the plates after being 
tested against bacteriophage Riley. The rest of the plates were fully lysed. Table 1 shows that 
mutants 1041, 1043, and 1221 were resistant to bacteriophage Riley. The other mutants either 
did not grow in culture well enough to plate or they were infected by Riley. The results of the 
spot tests are illustrated in Figure 8 where there is only a clearing in D, as indicated by the red 
circle, while A, B, and C did not have clearings. Mutants1041, 1043, and 1221 are resistant to 
bacteriophage Riley since the phage could not make a clearing in their lawns. There were some 
mutants, such as 1335, that did show some promise of being resistant. However the resistance 
results were inconsistent between each spot test, so they were disregarded.  
Table 1: Mutants Tested Against Bacteriophage Riley 
Mutant Resistant (Yes/No) 










1339 No growth 
A B 
C D 
Figure 8: Spot Tests: A) 1043 against Riley   B) 
1041 against Riley C) 1221 against Riley  D) 
1048 against Riley  
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DISCUSSION AND CONCLUSIONS 
 
From the data we obtained, we can conclude that transposon mutagenesis can be used 
to create phage resistant mutants of Gram-positive bacteria. From these mutants, three were 
found to be resistant to bacteriophage Riley. The BtK gene that encodes the receptor for Riley 
can be said to have been interrupted by the transposon by these results.  
Currently, there is a lack of information on Bacillus species surface receptors for phages. 
Analyzing the genes that allow for phages to interact with BtK will allow researchers to find 
specific phages that can be used for phage therapy. One reason why there is a lack of 
information for Bacillus RBPs is that the bacteria are Gram-positive, thus making it harder to 
complete mutagenesis and DNA extraction. 
 The Ez-Tn5 <R6kγori/Kan-2> transposon kit was chosen because it has been proven to 
be effective for multiple different strains of gram-positive bacteria including Bacillus subtilis. A 
problem that kept arising was that the yield of mutants was always small. The number of 
mutants created should have been in the hundreds, but only a total of 134 mutants were 
isolated on the KAN plates. We expected that the number of mutants needed to find a few that 
were resistant to Riley would have to be in the hundreds. Instead, we were able to isolate three 
that were consistently resistant. Having a large percentage of the mutants being resistant might 
mean that there are multiple receptors for this phage instead of just one.   
 Once the information about the genes that control the interaction between phages and 
the bacteria they infect has been found, it can be used to enhance phage therapy. Researchers 
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may be able to genetically engineer phages that bind more tightly to the receptor to guarantee 
high rate of infection. This can only be done if the researcher knows what protein controls the 
interactions and what makes up its macromolecular structure.  Researchers could also use this 
information to genetically engineer other phages that are highly virulent so that they can infect 
























Future work will be to extract DNA from the mutant cells, ligate the DNA with the 
transposon into a plasmid, and then complete plasmid transformation into E. coli. The 
transformation step will allow for the plasmid to be separated from the mutant’s chromosomal 
DNA. The DNA can then be extracted and purified from the E. coli cells to allow for it to be 
sequenced. The sequenced DNA can then be compared to the BtK library to find which protein 
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